在ESMI队列中注册的3型突变携带者脊髓小脑动症的药物治疗模式
Patrick Silva1,2,3,4, Marina A Costa1,4, Laetitia Gaspar1,5,2,3
1Center for Neuroscience and Cell Biology, University of Coimbra (CNC-UC), Coimbra, Portugal.
CNS drugs
|October 17, 2025
概括
这项研究揭示了SCA3型患者的药物使用模式,发现了多样化的使用方式,但没有影响疾病的进展. 标准化的临床实践对于管理SCA3症状至关重要.
科学领域:
- 神经科学是一个神经科学.
- 临床药理学 临床药理学
- 遗传学 遗传学 是一个
背景情况:
- 3型脊髓小脑缩症 (SCA3) 是一种常见的遗传性缩症,没有经批准的疾病修饰性治疗方法.
- 目前的管理重点是缓解症状,但指导方针有限,导致医生的自由裁量权.
- 缺乏关于SCA3症状管理的研究,阻碍了治疗标准化.
研究的目的:
- 与对照组相比,研究SCA3突变载体中药物使用模式.
- 分析疾病过程中药物开始的时间.
- 评估药物子类对SCA3疾病进展的影响.
主要方法:
- 药物使用在欧洲脊髓小脑脊柱性动3型/马查多-约瑟夫疾病倡议 (ESMI) 队列 (2016-2023) 中的回顾性横截面分析.
- 使用解剖治疗化学 (ATC) 系统分类的药物.
- 使用线性混合效应模型进行纵向分析,以评估药物对疾病进展的影响.
主要成果:
- 与对照组相比,SCA3患者使用了更多的维生素,矿物质补充剂,肌肉松剂和神经系统药物.
- 精神麻醉药和维生素是早期开始的;其他药物是在中后期开始使用的.
- 通常使用的药物子类对SCA3疾病进展没有显著的影响.
- 研究中心在药物使用方面发现了显著的差异.
结论:
- 这是第一个详细介绍SCA3突变携带者的药物使用模式的研究.
- 这些发现突显了当前SCA3管理方法的变化.
- 强调需要共同努力,以标准化SCA3的临床实践.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:14Brain Imaging
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).